Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe Uplisting is the next milestone for Cellceutix.
Feb 5 - Leo announces Nasdaq registration.
April 27 - BoD announced
April 27 - Form 8-A12B filed
Should hear something soon.
Added more today. I've added all the way up and now ironically all the way down.
Copy that. Thanks.
Nasdaq form filing was April 27. Someone on this board posted where it took another company just inside of 10 days to hear back for approval. So I'm guessing we should have an answer by Friday.
BS. All systems are a go over a Dana Farber according to last weeks report.
Well as for me I locked my office door...lol
Looks like Somebody doesn't want us to uplist.
My guess it's the ones with no dog in the hunt and 0 cost basis.
Clearly there is no support for this selling. The whole Aruda fiasco is a nightmare.
My DD says if you don't get in soon you'll be stupid.
Does "qualified" independent directors mean they have passed SEC scrutiny. Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin as qualified independent directors and committee members of the Company's Board of Directors.
Yes and it sounds to me like both primary and secondary end points are being met and then some.
To infinity and beyond said: How about the corporate update phrase some pts had stabilization of tumors? What is fanatastic here?
I'm just guessing but I would think if you were one of those stage 4 patients with tumor stabilization you would regard that news as pretty fantastic.
Thanks for the clarification.
A peer reviewed article based on the Phase 1 trial can't come out until the trial ends and bottom line data is available to the authors. Such articles take months to draft and months after that for review (hence per review) and publication.
It's possible that what they want to report and sdsicuss will be included in the ASCO presentation, which is considered a peer reviewed venue when a presentation is included in the conference published proceedings.
The whole discussion blaming a seller is nonsense we plainly just have no buyers. First we move up nicely from the P2b top line results and QIDP material event then investors are blindsided by P3 FDA delay and uncertainty. Share price has yet to recover. Now we may soon see fantastic results from Dana Farber as reported Jan20. We should soon get the Cellceutix anticipated presentation article on the safety and pharmacological effect of Kevetrin on multiple cancer lines as demonstrated in the clinical trial. Asco coming up next month hopefully article comes out right before. The science will eventually play out to a larger audience and make the longs and the lucky very rich. IMO June should be huge for ctix.
QIDP designations aren't handed out like candy, but apparently the FDA can still tell you to take a number.
My thoughts exactly. At this early point Leo wants members around him that he knows he can work with and trust.
You are fixated solely on today's price and not seeing past tomorrow. Leo is not on a train schedule, drugs especially very complicated drugs are extremely difficult to develop and bring to market for any pharma let alone a micro-cap. We now have a definitive human study that proves B works and K looks very promising. I for one was invested in a small otc working on pancreatic cancer therapy, after many years still no expanded studies pps remains in the pennies. Otc bio pharmaceuticals are a crap shoot, sage investors in the field have a better chance of seeing through the company propaganda.
Thanks, looking forward to the update tommorrow am.eom
Don't know if the author had a motive but maybe they are holding out for a later planned journal publication.
Completely agree with BK's assesment.
Leo reported: We are developing Brilacidin under a Qualified Infectious Disease Product (QIDP) designation from the FDA as a potential new and unique treatment for ABSSSI.
Upon the FDA accepting our proposals, we will commence Phase 3 trials of Brilacidin for ABSSSI.
Following examples shows QIDP designation is good to have on your side in the approval process.
On May 23, FDA approved Dalvance (dalbavancin), an injectable drug, administered intravenously in two doses one week apart.
On June 20, FDA approved Sivextro (tedizolid phosphate), available for intravenous and oral use, administered once daily for six days.
On August 6, FDA approved Orbactiv (oritavancin), an injectable drug administered as a single dose to comprise a full course of therapy.
In these approvals, the drug’s manufacturer was able to take advantage of recently enacted incentives to help bring new antimicrobials to market. Each of these drugs was approved after being designated as a Qualified Infectious Disease Product (QIDP) under the GAIN Act. As part of this QIDP designation, FDA’s review of the drug application was expedited.
And let the selling begin.
gotcha..thanks for the response.
Does wikipedia report Brilacidin as active against both Gram-positive and Gram-negative class of bacteria. Gram-negative is the more resistant of the two.
Thanks for all your effort. CTIX reports Brilacidin is active against both Gram-positive and Gram-negative class of bacteria. Gram-negative bacteria are in general resistant to antibiotics.
Even with all the positive data revealed last PR this thing goes on sale. Picked up more at 2.97.
It's another buying opportunity before the fireworks.
The minimum share price for the Nasdaq Capital Market is $2. I just hope we here back and soon.
Go back to what Leo reported in Jan20 PR, Ovarian Cancer Response -- Potential Major Breakthrough in Oncology. "[bThe Principal Investigators for the Kevetrin trial have requested that the Company start preparing a presentation to be used for an article on the safety and pharmacological effect of Kevetrin on multiple cancer lines as demonstrated in the clinical trial. I believe first uplist then the article is released showing pharmacological effect of Kevetrin. Then ASCO where Dr. Geoffrey Shapiro does the presentation.
I would like to say that there has been no RS with ctix to uplist. I would mention the 1:125 RS in 2013 to pad share price of another bio company that is popular right at the moment. Getting put on the big board will be life changing for our little undervalued darling.
I read the Nasdaq update as BoD finalized and uplisting will come any day. Couple that with a major drug pipeline progressing on all cylinders couldn't ask for more.
Leo said Mar24: The data on p21 are expected to be received in mid-April. Does Leo have data in hand? if not he will very soon.
Thanks for posting the link xoc.eom
Leo has it all under control...pity the fool who strikes the rock at this point.
IMO these conferences while good for showing progression to others in the field do very little for share price if any. Upcoming material events is what brings in new investors and value. Next comprehensive update to include: Nasdaq uplisting, Increased biomarker p21 measurment at the higher dose showing reactivation of p53(hoping for more patient responses), update on increased kevetrin dosing level for eleventh cohort, B-OM possibly underway and possibly an updated Brilacidin phase3 status post FDA meeting.
Sell...no thanks I haven't been holding this three years only to miss out on seeing the promised land. Go ctix.
The last pr read "additions to the Board of Directors" I now read that as vetting of all BoD was not quite done. I would believe that once this is complete Leo will be given a firm uplisting date which would be a news worthy event.
My question is why after 6months we still wait on FDA formal meeting. Brilacidin sits on a shelf waiting on a meeting burdened sloth like government entity to back and forth with Leo. What happened to our fast track or the huge push from the administration for new antibiotics.
Will Leo put out a firm uplisting date ahead of the update? Seems like the reasonable thing to do.
I believe Leo's wording: "additions to the Board of Directors, and uplisting to the Nasdaq exchange" as a done deal. My opinion is that since these new additions were being vetted by the Nasdaq seems uplisting is a go ahead.